MAIA BIOTECHNOLOGY INC

Company Overview

MAIA Biotechnology is a clinical-stage biotechnology company developing THIO (ateganosine), a telomere-targeting small molecule intended to induce telomere dysfunction in TERT+ solid tumors and to prime tumors for immune checkpoint inhibitors. The company is advancing THIO in Phase 2/approaching Phase 3 in NSCLC (planned THIO-104 start in 2025) with additional planned combination studies in HCC, CRC and SCLC alongside partners BeiGene and others. MAIA is a virtual, science-driven shop (13 FTEs at 12/31/2024) that outsources manufacturing and many clinical functions, holds UTSW licenses and a growing patent estate, and is dependent on clinical milestones, collaborator supply agreements, and external capital to fund pivotal development.

Executive Compensation Practices

Given MAIA’s clinical-stage profile, executive pay is likely heavily equity‑ and milestone‑weighted: the filings show material stock‑based compensation and periodic option/warrant issuances, and management explicitly cites option/warrant valuation as a significant accounting judgment. Compensation decisions will be driven by clinical and regulatory milestones (dose selection, interim signals, pivotal start and potential accelerated filings) and by capital markets activity (private placements, ATM offerings) that affect share count and valuation. The small headcount and virtual operating model typically mean lower fixed cash pay and higher long‑dated, performance‑contingent awards; the company’s stated cash constraints and going‑concern disclosure increase the likelihood management compensation leans toward equity to conserve cash. Finally, collaboration agreements (e.g., Regeneron, BeiGene) can create milestone payments or revenue-sharing events that may be tied to executive performance measures or trigger additional incentive payouts.

Insider Trading Considerations

Insider trading at MAIA is likely influenced by frequent financing activity (ATM sales, private placements) and by binary clinical readouts—both are material events that drive share price and create natural blackout periods around trial enrollment, interim analyses and pivotal starts. Past large non‑cash warrant revaluations (a $6.68M adverse remeasurement in 2024) and subsequent swings in reported losses underline that insiders may time option exercises or sales around periods when warrant valuations and accounting items are understood by the market. Because MAIA is small with concentrated ownership and routine equity grants, expect Form 4 activity for option exercises, secondary sales following financings, and occasional use of Rule 10b5‑1 plans; conversely, strict trading windows and disclosure obligations should be observed given the materiality of clinical/regulatory milestones and collaborator notices. Regulatory considerations — FDA Fast Track, orphan designations and dependence on third‑party suppliers — make clinical data and supply agreements particularly sensitive catalysts for insider trades.